Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients
| Autor: | Jazag Amarsanaa, Tulgaa Khosbayar, Shih-Jer Hsu, Nyamsuren Naranzul, Oidov Baatarkhuu, Jia-Horng Kao, Tai-Chung Tseng, Sukhee Enkhzaya, Dogsom Ivshinkhorol, Damba Enkhtuya, Badarch Jargalsaikhan, Tzu-San Wang, Cheng-Hsueh Tsai, You-Yu Lin |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Ledipasvir
Adult Male medicine.medical_specialty Sofosbuvir Genotype Hepatitis C virus Viral quasispecies medicine.disease_cause Gastroenterology Antiviral Agents 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Chronic hepatitis Internal medicine Drug Resistance Viral medicine Humans Treatment Failure NS5A Aged lcsh:R5-920 Fluorenes business.industry High-Throughput Nucleotide Sequencing General Medicine Mongolia Hepatitis C Chronic Middle Aged Treatment Outcome chemistry 030220 oncology & carcinogenesis LEDIPASVIR/SOFOSBUVIR 030211 gastroenterology & hepatology Benzimidazoles Drug Therapy Combination Female lcsh:Medicine (General) business Uridine Monophosphate medicine.drug |
| Zdroj: | Journal of the Formosan Medical Association, Vol 119, Iss 3, Pp 712-719 (2020) |
| ISSN: | 0929-6646 |
| Popis: | Background: Mongolia has the highest prevalence of hepatitis C virus (HCV) infection worldwide. Ledipasvir/sofosbuvir (LDV/SOF) was introduced to Mongolia since 2016 for HCV eradication. It has been reported that HCV resistance-associated substitutions (RASs) would affect the effectiveness of LDV/SOF in western chronic hepatitis C (CHC) patients. We thus investigated the effectiveness of LDV/SOF and the impact of RAS on the treatment outcome in Mongolian CHC patients. Methods: Patients with genotype (GT) 1b HCV infection were prospectively enrolled in Mongolia and treated with LDV/SOF for 12 weeks. The proportion of pre-treatment NS5A Y93H RAS in viral quasispecies was measured with next-generation sequencing. The endpoint of LDV/SOF effectiveness was sustained virological response at post-treatment week 12 (SVR12). Results: A total of 94 CHC patients were evaluated. The baseline Y93H proportion was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|